RecruitingEarly Phase 1NCT06744816

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study


Sponsor

M.D. Anderson Cancer Center

Enrollment

20 participants

Start Date

Dec 11, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Qutenza Patch for people with peripheral neuropathy due to chemotherapy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGQutenza Patch

Given topical


Locations(1)

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06744816


Related Trials